CA-DENODO
21.3.2022 09:02:09 CET | Business Wire | Press release
Denodo , the leader in data management, today announced that its subscription license revenue grew more than 50 percent year-over-year, as the company moved close to becoming a 100 percent subscription-based revenue business. While new customer acquisitions and existing customer expansion remained strong and steady year-over-year, Denodo’s cloud marketplace presence encountered the fastest growth with more than 300 transactions in 2021.
Denodo customers’ positive sentiment about its product, services, and support was once again captured as part of the Gartner Peer Insights reviews and, as a result, Denodo has again been recognized as a Customer's Choice in the Gartner Peer Insights “Voice of the Customer”: Data Integration Tools , 28 January 2022. With an overall rating of 4.4 out of 5, Denodo is one of the only three Gartner® Magic Quadrant™ for Data Integration Tools Leaders to receive Customers’ Choice for 2022 and is the third highest rated data integration vendor in the report. Denodo was also positioned as a Leader for the Second Consecutive Year in the 2021 Gartner® Magic Quadrant™ for Data Integration Tools . During the same year, Denodo customers and Denodo Platform were bestowed with numerous awards and recognitions, such as TDWI Best Practices Award, Ventana Research Digital Leadership Award, and DBTA Readers' Choice Awards, to name a few.
During 2021, Denodo added important brand names to its already stellar global customer roster, including Credit Suisse, Deutsche Bank, Toyota Financial Services, Johnson & Johnson, and Goldwind. During the same period, Denodo Platform version 8, which was launched in 2020 to offer enterprises the ability to deploy enterprise grade logical data fabric, added some major capabilities including AI & Recommendations and Advanced Semantics. These new additions help enterprise data and analytics teams automate frequently used data management functions, improve collaboration between data stewards and business users, and secure data access.
The Company extended its worldwide footprint to 25 offices spanning 20 countries, including new offices in South Korea, Sweden, Netherlands and Belgium. During the same year, strategic technology and consulting alliances also intensified as marked by a 56 percent increase in new signed partner agreements and significant growth within current partnerships, bringing a 192 percent increase in revenue from this important channel.
“Every company rooted in making data-driven business decisions is realizing that it is impractical to move all their data in a single repository such as a cloud data lake or cloud data warehouse,” said Angel Viña, founder and CEO of Denodo. “That is exactly why they selected Denodo Platform to build their logical data fabric to integrate, manage and deliver their enterprise data to business stakeholders. We thank our partners and customers alike for their continued support for our platform and we are looking forward to helping hundreds of new customers who are looking to make insights-driven business decisions and support their enterprise data across cloud and regional boundaries.”
Please Tweet: #dataintegration leader @denodo announces double-digit revenue growth and strong momentum in customer acquisition through #amazon #google and #azure marketplaces
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using logical approach to enable self-service BI, advanced analytics, hybrid/multi-cloud integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprise and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom